title: Prognostic value of morphology and hormone receptor status in breast cancer - a population-based study.
abstract: We analysed the 5-year relative survival among 4473 breast cancer cases diagnosed in 1990-1992 from cancer registries in Estonia, France, Italy, Spain, the Netherlands and the UK. Among eight categories based on ICD-O codes (infiltrating ductal carcinoma, lobular plus mixed carcinoma, comedocarcinoma, 'special types', medullary carcinoma, not otherwise specified (NOS) carcinoma, other carcinoma and cancer without microscopic confirmation), the 5-year relative survival ranged from 66% (95% CI 61-71) for NOS carcinoma to 95% (95% CI 90-100) for special types (tubular, apocrine, cribriform, papillary, mucinous and signet ring cell); 27% (95% CI 18-36) for cases without microscopic confirmation. Differences in 5-year relative survival by tumor morphology and hormone receptor status were modelled using a multiple regression approach based on generalised linear models. Morphology and hormone receptor status were confirmed as significant survival predictors in this population-based study, even after adjusting for age and stage at diagnosis.
authors.affiliation: Epidemiology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, I-20133 Milano, Italy. claudia.allemani@istitutotumori.mi.it
authors.forename: C
authors.initials: C
authors.lastname: Allemani
authors.forename: M
authors.initials: M
authors.lastname: Sant
authors.forename: F
authors.initials: F
authors.lastname: Berrino
authors.forename: T
authors.initials: T
authors.lastname: Aareleid
authors.forename: G
authors.initials: G
authors.lastname: Chaplain
authors.forename: J W
authors.initials: JW
authors.lastname: Coebergh
authors.forename: M
authors.initials: M
authors.lastname: Colonna
authors.forename: P
authors.initials: P
authors.lastname: Contiero
authors.forename: A
authors.initials: A
authors.lastname: Danzon
authors.forename: M
authors.initials: M
authors.lastname: Federico
authors.forename: L
authors.initials: L
authors.lastname: Gafà
authors.forename: P
authors.initials: P
authors.lastname: Grosclaude
authors.forename: G
authors.initials: G
authors.lastname: Hédelin
authors.forename: J
authors.initials: J
authors.lastname: Macè-Lesech
authors.forename: C M
authors.initials: CM
authors.lastname: Garcia
authors.forename: E
authors.initials: E
authors.lastname: Paci
authors.forename: N
authors.initials: N
authors.lastname: Raverdy
authors.forename: B
authors.initials: B
authors.lastname: Tretarre
authors.forename: E M I
authors.initials: EM
authors.lastname: Williams
mesh_terms: D000368:Aged; D001943:Breast Neoplasms / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000473:pathology*; D018275:Carcinoma, Lobular / Q000473:pathology*; D005060:Europe; D005260:Female; D006801:Humans; D008875:Middle Aged; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D012042:Registries / Q000706:statistics & numerical data*; D012307:Risk Factors; D016019:Survival Analysis
chemical_list: D011960:Receptors, Estrogen; D011980:Receptors, Progesterone